692 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 692 shares of the biopharmaceutical company’s stock, valued at approximately $519,000.

Several other large investors have also recently added to or reduced their stakes in REGN. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $5,682,636,000. Legal & General Group Plc purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $473,872,000. Bank of New York Mellon Corp acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $472,950,000. Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $323,249,000. Finally, Man Group plc acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $272,460,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. UBS Group upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $660.00 to $978.00 in a report on Thursday, October 15th. Piper Sandler boosted their target price on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. TD Cowen increased their price objective on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Finally, Jefferies Financial Group raised their price objective on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

View Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $955.47 on Monday. The stock has a market capitalization of $98.84 billion, a P/E ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $816.17 and a two-hundred day moving average price of $747.36. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter last year, the company posted $11.83 earnings per share. The company’s revenue for the quarter was up 36.3% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Joseph J. Larosa sold 4,466 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the sale, the executive vice president owned 38,906 shares in the company, valued at $37,563,353.94. This represents a 10.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total value of $360,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $542,700. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock worth $25,025,950 in the last quarter. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.